Inhibition of indoxyl sulfate-induced intrarenal renin-angiotensin system activation: targeting the aryl hydrocarbon receptor

Muhammad Firman Akbar

Department of General Health Service, Sahabat Sehat Clinic, West Nusa Tenggara, Indonesia, Department of Medicine, University of Melbourne St. Vincent’s Hospital Melbourne, Australia

*Correspondence: MF Akbar; Tel: +61 452-36-2908, E-mail: mfakbar@connect.hku.hk, akbarm1@student.unimelb.edu.au

Indoxyl sulfate, a protein-bound uremic toxin, leads to CKD (chronic kidney disease) progression and its complications through the activation of AhR (aryl hydrocarbon receptor) and RAS (renin-angiotensin system). Inhibition of these pathways may slow the development of CKD and CKD-associated complications.

Received 20 May 2017
Revised 17 Jun 2017
Accepted 28 Jun 2017

Keywords
Chronic Kidney Disease, Indoxyl Sulfate, Aryl Hydrocarbon Receptor, Renin-Angiotensin System

Copyright © 2017 Muhammad Firman Akbar
It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).
This paper meets the requirement of KS X ISO 9706, ISO 9706-1994 and ANSI/NISO Z.39.48-1992 (Permanence of Paper).

This article was reviewed by peer experts who are not TCP editors.
In the second study, Watanabe et al. investigated the effect of IS toxicity on human umbilical cord blood vessels. This study aimed to prove that IS toxicity is caused by the activation of the aryl hydrocarbon receptor (AhR), a protein often involved in herbicide poisoning called agent orange (used as a chemical weapon in 1960’s Vietnam War). It is reasonable to suggest that IS activates the AhR, as IS and agent orange are both categorized as toxins. The main difference is that IS is produced within the body whereas agent orange is an external toxin. The mechanism of cell damage by IS was found to be much the same as the mechanism mediated by oxidative stress and inflammation. This study also showed that blood vessels exposed to IS attract white blood cells which contribute to inflammation. Later, Watanabe et al. tested two drugs which block the AhR, and these treatments reduced the effects of IS.

Based on above two studies, IS accelerates kidney damage through the AhR and RAS pathways. However, the exact mechanism has not been known yet. However, some data have highlighted that IS strongly interacts with and activates the AhR (Fig. 1). RAS activity also increases while the AhR is activated. [6,7] In an experimental study of mice exposed to IS, Ichii et al. [8] showed that the AhR pathway leads to glomerular damage, microalbuminuria, increased the synthesis of mesangial matrix, mesangial cell lysis, tubulointerstitial lesions, vascular damage, and the activation of genes responsible for inflammation. In addition, a cell culture study of podocytes showed that IS caused cell injury, affected the viability of cells, and stimulated the release of cytokines that contribute to inflammation.[8]

Ng et al.[9] also investigated the effect of IS-stimulated AhR activation on RAS-counteracting pathways. The Mas receptor is a protein that counteracts the harmful effect of the RAS. Using human proximal tubular cell cultures, Ng and coworkers revealed that IS reduces the expression of the Mas receptor by activating AhR. From this, we can hypothesize that the interaction between IS and the AhR may precipitate the activation of the RAS pathway, which results in fibrosis and inflammation.

There are some questions following this hypothesis. First, does the pathway described above also affect heart and blood vessels? In fact, the increased level of IS in CKD is related to heart abnormalities and the narrowing and stiffening of blood vessels. Studies of cell cultures and animal models revealed that IS also induces fibrosis and inflammation in the heart and blood vessels. [10,11] This indicates that cell damage in the heart and blood vessels is likely to be improved by blocking the AhR.

In addition, the efficacy of AhR-targeting drugs must be examined. Sun et al.[3] showed satisfactory result of using losartan, an RAS-targeting drug, in cells and mice. However, some experts argue that losartan is less effective in blocking the RAS pathway, as some patients with CKD still develop to the terminal stage and die of heart failure even after these drugs are administered. This evidence emphasizes the need for an alternative method of minimizing RAS stimulation in CKD. It is hoped that an AhR blocker can also reduce the expression of the RAS pathway and lead to improved therapies for CKD.

Although these two studies only provide the evidence that IS has effects on CKD development and complications, it is hopeful that providing an effective AhR-targeting treatment may enhance the choice of drugs designed to target the RAS pathway.

Acknowledgements
None.

Conflicts of interests
-Authors: Nothing to declare
-Reviewers: Nothing to declare
-Editors: Nothing to declare

References
1. Mills KT, Xu Y, Zhang W, Bundy JD, Chen CS, Kelly TN, et al. A systematic analysis of world-wide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int 2015;88:950-957. doi: 10.1038/ki.2015.230.
2. Niwa T. Role of indoxyl sulfate in the progression of chronic kidney disease.
Inhibition of IS-induced intrarenal RAS activation: Targeting the AhR

and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Ther Apher Dial 2011;15:120-124. doi: 10.1111/j.1744-9987.2010.00882.x.

3. Sun CY, Chang SC, Wu MS. Uremic toxins induce kidney fibrosis by activating intrarenal renin–angiotensin–aldosterone system associated epithelial-tomesenchymal transition. PLoS One 2012;7:e4026. doi: 10.1371/journal.pone.004026.

4. Watanabe I, Tatebe J, Namba S, Koizumi M, Yamazaki J, Morita T. Activation of aryl hydrocarbon receptor mediates indoxyl sulfate-induced monocyte chemoattractant protein-1 expression in human umbilical vein endothelial cells. Circ J 2013;77:224-230. doi: 10.1253/circj.CJ-12-0647.

5. Siragy HM, Carey RM. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol 2010;31:541-550. doi: 10.1159/000313363.

6. Schroeder JC, DiNatale BC, Murray IA, Flattery CA, Liu Q, Laurenzana EM, et al. The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry 2010;49:393-400. doi: 10.1021/bi901786x.

7. Zhang N, Agbor LN, Scott JA, Zabolowski T, Elased KM, Trujillo A, et al. An activated renin-angiotensin system maintains normal blood pressure in aryl hydrocarbon receptor heterozygous mice but not in null mice. Biochem Pharmacol 2010;80:197-204. doi: 10.1016/j.bcp.2010.03.023.

8. Ichii O, Otsuka-Kanazawa S, Nakamura T, Ileno M, Kon Y, Chen W, et al. Podocyte injury caused by indoxyl sulfate, a uremic toxin and aryl-hydrocarbon receptor ligand. PLoS One 2014;9:e108448. doi: 10.1371/journal.pone.0108448.

9. Ng HY, Yisireyili M, Salto S, Lee CT, Adelbi-ke Ye, Nishijima F, et al. Indoxyl sulfate downregulates expression of Mas receptor via OAT3/AhR/Stat3 pathway in proximal tubular cells. PLoS One 2014;9:e91517. doi: 10.1371/journal.pone.0091517.

10. Lekawanvijit S, Kompa AR, Manabe M, Wang BH, Langham RG, Nishijima F, et al. Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS One 2012;7:e41281. doi: 10.1371/journal.pone.0041281.

11. Ito S, Osaka M, Edamatsu T, Itoh Y, Yoshida M. Crucial Role of the Aryl Hydrocarbon Receptor (AhR) in Indoxyl Sulfate-Induced Vascular Inflammation. J Atheroscler Thromb 2016;23:960-975. doi: 10.5551/jat.34482.

12. Pernomian L, da Silva CHTP. Current basis for discovery and development of aryl hydrocarbon receptor antagonists for experimental and therapeutic use in atherosclerosis. Eur J Pharmacol 2015;764:118-123. doi: 10.1016/j.ejphar.2015.06.058.